PsyRx: What the 2026 financing will cost shareholders
The post-balance-sheet financing package could bring PsyRx up to NIS 12.26 million, almost the company’s entire current market value, but the cost to existing holders is not just a 27.09% equity line. It includes immediate dilution, a long option tail, ratchet protection, and real influence over the next financing round.
The main article argued that PsyRx’s urgent 2026 question is not just whether the science is interesting, but who gets to fund the path to the first human trial. This follow-up isolates the price of that bridge. Not the need for it, but what existing shareholders are giving up in order to get it.
The short answer is fairly blunt. The headline numbers, 27.09% of the equity on an undiluted basis and 28.96% on a fully diluted basis, sound heavy but still digestible. In practice, that is only part of the bill. Translated into the live share base today, 10,226,146 shares, the signed package already adds 3.8 million immediate shares. That is about 37.2% more shares before one option is exercised and before one ratchet share is issued.
The cash layer makes the same point. The investment and the additional investment together bring NIS 5.15 million. If all the allocated options are exercised, the company could receive another NIS 7.111 million. That is about NIS 12.26 million in total. As of April 3, 2026, PsyRx’s market value stood at about NIS 12.4 million. In other words, the full financing package is almost the size of the whole company’s current market capitalization.
That is the core point. PsyRx is not raising a small amount of capital to polish an existing path. It is almost rewriting the public equity layer in order to buy time for the trial.
| Layer | Cash to company | Securities or rights | What it means for current holders |
|---|---|---|---|
| Investment and additional investment | NIS 5.15 million | 3.8 million shares | Immediate dilution of about 37.2% versus the current live share base |
| Option layer | Up to NIS 7.111 million if fully exercised | 4,547,020 options | If the story progresses, shareholders get diluted again to bring in the next cash tranche |
| Ratchet protection | No immediate cash | 659,366 rights into shares on the first-investment shares | If the share price is weak at the test date, the company compensates the bridge investors with more equity |
| Financing restrictions | No immediate cash | Right of first refusal, debt and pledge restrictions, raise cap | The investors funding the 2026 bridge also influence the next financing round |
27% is the investor stake, not the shareholder bill
The 27.09% number describes the investors’ stake after the allocation. It does not describe what a current shareholder feels while sitting today on a live layer of 10.226 million shares. From that perspective, the initial issuance of 3.8 million shares takes the share count to about 14.03 million before options or ratchet even enter the discussion.
The 28.96% fully diluted figure hides even more. To get there, the denominator already includes older layers of rights and options. In the meeting materials, even before the new deal, the fully diluted share count already reflected 10,958,777 rights and 905,290 options. So the investor percentage looks smaller than the economic change felt by the current common-share layer.
Translated into the current share base, this financing thread alone reserves room for up to about 9.01 million new shares from the deal itself: 3.8 million immediate shares, 4,547,020 options, and up to 659,366 ratchet shares. That equals about 88.1% of the current live share count. Even if not every layer is ultimately exercised, this is no longer a story of “some extra dilution.” It is a financing package that can materially change the ownership economics before the first real proof point arrives.
The practical meaning is that the existing shareholder is not just selling a percentage of the company. They are selling three separate layers: immediate equity in order to survive, optionality in order to fund the next stage, and downside protection for the investors who come in first.
The real price is not NIS 1.25
It is easy to look at the nominal NIS 1.25 share price and conclude that the gap versus the market is not extreme. That is a shallow reading. In the shareholder-meeting materials, the company itself calculated that the average effective price, once the value of the allocated options and rights is taken into account, was only about 66.88 agorot per share. Against a market price of 132.9 agorot near publication of the notice, the company itself described a ratio of about 50.32%.
That matters because it breaks the simple argument that the company is raising near market. It is not. It is raising through a package in which the nominal share price is only one part of the economics. The rest travels through options, ratchet protection, and priority over the next financing round.
The second leg of the deal sharpens that point. In the February meeting notice, the company still described an additional-investment right of up to NIS 3 million at NIS 1.25 per share. In the annual report, which already reflects the March amendments, that leg shrinks to NIS 1.65 million, but arrives together with 1,000,000 shares and 1,457,020 series C options at an exercise price of NIS 1.65, vested immediately for 18 months. In other words, the second leg brings less upfront cash than the original version suggested, but it still preserves a very material option tail.
The ratchet makes the package even more asymmetric. On the first-investment shares, the investors receive 659,366 rights into shares. The test date is the earlier of 30 months from completion of the transaction or 60 days after publication of the final results of the clinical trial. If the average share price over the 30 trading days before that date is below NIS 2, the investors are entitled to additional shares, subject to a ceiling.
At the latest local market price, NIS 1.21, the stock is still well below that NIS 2 threshold. That does not activate the ratchet today, because the test happens only later, but it does show that the protection granted to the first-money investors is not remote or theoretical. It sits inside a price range the stock is already living in.
The investors funding the bridge also get priority over the next bridge
This is where the deal moves from normal dilution into something deeper. Under the terms reflected in the annual report, from signing until 60 days after the test date, the company is limited in additional equity raises to a total ceiling of NIS 1.35 million of actual cash unless the raise is done at an effective price of NIS 2 per share or more. Rights offerings are excluded from that cap. During that same period it may not take debt or pledge assets without Grupman’s consent. On top of that, Grupman receives a right of first refusal in any private placement until the test date.
That matters even more because the original meeting materials still described room for up to NIS 3 million of additional equity raises without restriction, whereas the final frame described in the annual report narrows the free-financing room to NIS 1.35 million of actual cash. So the company did not just raise money on expensive terms. It also narrowed part of its path to the next raise unless the first investors agree.
There is a clear financing logic here. Whoever puts in the first money wants protection against an even cheaper round arriving immediately afterwards. But for existing shareholders this is no longer only a price question. It is a question of financing freedom. If PsyRx needs more capital before the stock rises above NIS 2 or before the test date passes, it will come to that table from within a much tighter set of options.
The potential control layer completes the picture. If shareholders approve the agreement, the private placement is supposed to grant Eliran Grupman and Roy Rubinenko a control bloc in the company. So this is not only a raise. It also signals who may sit at the layer of influence over financing, the board, and the way future upside is ultimately divided if the first trial succeeds.
Bottom line
The real cost of the 2026 financing is not just an ownership percentage. It is a four-part package built together: immediate dilution to secure NIS 5.15 million, an option tail to bring another NIS 7.111 million if the company progresses, ratchet protection if the share stays weak, and restrictions that place the bridge investors at the front of any further financing.
One can reasonably argue that this price is still rational, because without the bridge the company may not reach the first proof point at all. But it needs to be read correctly. In PsyRx, whoever funds the road to the first human data point is not just buying shares. They are buying part of the company, part of the upside, and part of the freedom around the next capital raise.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.